CDR2 and neoplasm: If the tumor is not consistent with the phenotype of a cerebellar syndrome or the antibody (e.g., gastric adenocarcinoma in a patient with cerebellar ataxia and Yo-antibodies), cognate antigen expression by the tumor has to be demonstrated [6].